NASDAQ:IFRX - Inflarx Stock Price, Forecast & News

Inflarx trades on the NASDAQ under the ticker symbol "IFRX."

Inflarx NV (NASDAQ:IFRX) issued its quarterly earnings data on Thursday, August, 9th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.24. View Inflarx's Earnings History.

Inflarx is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Inflarx.

9 brokerages have issued twelve-month price targets for Inflarx's shares. Their forecasts range from $5.00 to $44.00. On average, they expect Inflarx's stock price to reach $12.50 in the next year. This suggests a possible upside of 174.7% from the stock's current price. View Analyst Price Targets for Inflarx.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inflarx in the last year. There are currently 2 sell ratings and 7 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Inflarx.

News stories about IFRX stock have trended very positive on Saturday, according to InfoTrie. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Inflarx earned a news impact score of 3.1 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Inflarx.

Inflarx saw a decrease in short interest in the month of January. As of January 31st, there was short interest totalling 816,000 shares, a decrease of 21.5% from the January 15th total of 1,040,000 shares. Based on an average trading volume of 685,500 shares, the days-to-cover ratio is currently 1.2 days. Currently, 4.5% of the shares of the company are short sold. View Inflarx's Current Options Chain.

Some companies that are related to Inflarx include Prothena (PRTA), BioDelivery Sciences International (BDSI), Satsuma Pharmaceuticals (STSA), BioSpecifics Technologies (BSTC), Organogenesis (ORGO), Sinovac Biotech (SVA), Cue Biopharma (CUE), Beyondspring (BYSI), ProQR Therapeutics (PRQR), Merus (MRUS), Progenics Pharmaceuticals (PGNX), Innate Pharma (IPHYF), Mersana Therapeutics (MRSN), Fulcrum Therapeutics (FULC) and OrganiGram (OGI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Inflarx investors own include Global Blood Therapeutics (GBT), AbbVie (ABBV), NovaBay Pharmaceuticals (NBY), ACADIA Pharmaceuticals (ACAD), Agile Therapeutics (AGRX), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Novavax (NVAX), Sarepta Therapeutics (SRPT) and Pfizer (PFE).

(IFRX) raised $100 million in an initial public offering (IPO) on Wednesday, November 8th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

Inflarx's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Ikarian Capital LLC (1.38%), Goldman Sachs Group Inc. (0.64%), Geode Capital Management LLC (0.34%), Oxford Asset Management LLP (0.17%) and Tower Research Capital LLC TRC (0.04%).

IFRX stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc..

IFRX stock was acquired by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Geode Capital Management LLC, Oxford Asset Management LLP and Tower Research Capital LLC TRC .

Shares of IFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IFRX stock can currently be purchased for approximately $4.55.

Inflarx has a market capitalization of $118.12 million. The company earns $-35,210,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. Inflarx employs 36 workers across the globe.View Additional Information About Inflarx.

The official website for Inflarx is http://www.inflarx.de/.

Inflarx's mailing address is WINZERLAER STR. 2, JENA 2M, 07745. The company can be reached via phone at 49-36-4150-8180.